Literature DB >> 18668623

The clinical spectrum of freezing of gait in Parkinson's disease.

Yasuyuki Okuma1, Nobuo Yanagisawa.   

Abstract

Freezing of gait (FOG) is a common and very disabling symptom in Parkinson's disease (PD). It is usually observed in the advanced stage of the disease, although a mild form can be seen in the early stage. Although some studies have suggested that longer duration of dopaminergic treatment is associated with FOG, the disease progression alone may be responsible for the development of FOG. FOG can be experienced on turning, in narrow spaces, while reaching a destination, and in stressful situations. In PD, FOG is strongly associated with motor fluctuation. FOG is commonly observed in the "off" state and is observed less frequently in the "on" state. Dual tasking (cognitive load) aggravates FOG. Visual or auditory cues often resolve FOG. Analysis of gait revealed that the stepping rhythm suddenly jumps into high frequency (4-5 Hz) in FOG (hastening), and that floor reaction forces are disregulated. Since the hastening phenomenon was also reported in patients with lesions in the striatum and/or the frontal lobe, fronto-basal ganglia projections are considered essential for FOG. Careful observation and gait pattern analysis may lead to a successful management of individual PD patients with FOG. (c) 2008 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18668623     DOI: 10.1002/mds.21934

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  23 in total

1.  Heart rate changes during freezing of gait in patients with Parkinson's disease.

Authors:  Inbal Maidan; Meir Plotnik; Anat Mirelman; Aner Weiss; Nir Giladi; Jeffrey M Hausdorff
Journal:  Mov Disord       Date:  2010-10-30       Impact factor: 10.338

2.  Development of a VR-based treadmill control interface for gait assessment of patients with Parkinson's disease.

Authors:  Hyung-Soon Park; Jung Won Yoon; Jonghyun Kim; Kazumi Iseki; Mark Hallett
Journal:  IEEE Int Conf Rehabil Robot       Date:  2011

3.  Regional gray matter atrophy in patients with Parkinson disease and freezing of gait.

Authors:  A Tessitore; M Amboni; G Cirillo; D Corbo; M Picillo; A Russo; C Vitale; G Santangelo; R Erro; M Cirillo; F Esposito; P Barone; G Tedeschi
Journal:  AJNR Am J Neuroradiol       Date:  2012-04-26       Impact factor: 3.825

4.  A pilot study: influence of visual cue color on freezing of gait in persons with Parkinson's disease.

Authors:  Mon S Bryant; Diana H Rintala; Eugene C Lai; Elizabeth J Protas
Journal:  Disabil Rehabil Assist Technol       Date:  2010

Review 5.  Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?

Authors:  Albert Y Hung; Michael A Schwarzschild
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

6.  Assessing mobility at home in people with early Parkinson's disease using an instrumented Timed Up and Go test.

Authors:  Cris Zampieri; Arash Salarian; Patricia Carlson-Kuhta; John G Nutt; Fay B Horak
Journal:  Parkinsonism Relat Disord       Date:  2010-08-30       Impact factor: 4.891

Review 7.  Motor Complications of Dopaminergic Medications in Parkinson's Disease.

Authors:  Maria Eliza Freitas; Christopher W Hess; Susan H Fox
Journal:  Semin Neurol       Date:  2017-05-16       Impact factor: 3.420

8.  Reduction of freezing of gait in Parkinson's disease by repetitive robot-assisted treadmill training: a pilot study.

Authors:  Albert C Lo; Victoria C Chang; Milena A Gianfrancesco; Joseph H Friedman; Tara S Patterson; Douglas F Benedicto
Journal:  J Neuroeng Rehabil       Date:  2010-10-14       Impact factor: 4.262

9.  Parkinson's Disease and Its Management: Part 4: Treatment of Motor Complications.

Authors:  George DeMaagd; Ashok Philip
Journal:  P T       Date:  2015-11

10.  Association of freezing of gait and clinical features in patients with Parkinson's disease.

Authors:  Tülin Aktürk; Hayat Güven; Bülent Güven; Selçuk Çomoğlu
Journal:  Acta Neurol Belg       Date:  2019-10-25       Impact factor: 2.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.